Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Neovii logo — company profile

Neovii

Founded 2003 Switzerland Switzerland 111 employees Biotechnology, Health Care

General Information

Company Name Neovii
Founded Year 2003
Location Switzerland Switzerland +2
Employees 111
Industries Biotechnology, Health Care
Social

Get notified when Neovii moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Neovii

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. The company's lead product, Grafalon®, has been making a significant impact for over 30 years, being utilized to treat patients and widely available in more than 40 countries worldwide. It has gained approval for use in immunosuppressive therapies for prevention of graft-versus-host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation, and in the treatment of aplastic anemia. Founded in 2003 and headquartered in Switzerland, Neovii operates within the Biotechnology and Health Care industries. The company's established presence in the global market signifies a strong track record and potential for continued growth and innovation. While specific details regarding the last investment and associated investors are not currently available, Neovii's extensive experience and widespread usage of Grafalon® position it as an attractive venture for potential investment within the biotechnology and healthcare sectors.

Taxonomy: polyclonal antibody, immunosuppressive therapy, organ transplantation, hematology, oncology, Grafalon, pharmaceutical, global leader, stem cell transplantation, solid organ transplantation, aplastic anemia, clinical therapy, medical treatment, global presence

No funding data available for Neovii yet.

Get notified when Neovii raises funding

Neovii Alternatives & Competitors

Neovii vs
NextImmune
NextImmune

Empowering Treatment with Superior Safety and Efficacy in Autoimmune and Transplant Care

Grant
Biotechnology, Health Care
Neovii vs
LifeLink Foundation
LifeLink Foundation United States

Saving and enhancing lives through organ and tissue donation.

170 employees
Health Care
Neovii vs
Advanced Life Solutions
Advanced Life Solutions France

At ALS we ensure that every organ is an opportunity for another patient to live. With ALS expect mor...

3 employees

FAQ About Neovii

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosu...
Neovii was founded in 2003.
Neovii is headquartered in Switzerland.
Neovii operates in the following industries: Biotechnology, Health Care.
Neovii has approximately 111 employees.
Top alternatives and competitors to Neovii include NextImmune, LifeLink Foundation , Advanced Life Solutions, Qihan Biotechnology Co., Ltd., ISMETT. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neovii and NextImmune are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neovii and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy